# Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis

## TL;DR

This study reviews how well JAK inhibitors work for treating large vessel vasculitis, finding they are effective and safe.

## Contribution

A systematic review and meta-analysis of JAK inhibitors for large vessel vasculitis, including both GCA and TAK.

## Key findings

- Pooled 12-month remission rate of 80.1% in large vessel vasculitis patients.
- Relapse rates were 11.3% overall, with higher rates in Takayasu’s Arteritis (22.9%).
- Adverse event-related discontinuation was low at 4.4% across both conditions.

## Abstract

This meta-analysis evaluates Janus Kinase (JAK) inhibitors’ efficacy and safety in large vessel vasculitis (LVV), encompassing Giant Cell Arteritis (GCA) and Takayasu’s Arteritis (TAK).

Registered on PROSPERO (CRD42024575313), four databases were systematically searched for randomized controlled trials (RCTs) and observational studies. Outcomes included remission/relapse rates and adverse events, assessed with sensitivity/publication bias analyses.

Five studies (107 patients: 65 GCA, 42 TAK) showed pooled 12-month remission rates of 80.1 % (95 % CI: 68.3–92.0), with subgroup rates of 87.3 % (GCA) and 69.6 % (TAK). Relapse rates were 11.3 % overall (2.5 % GCA vs. 22.9 % TAK). Adverse event-related discontinuation was 4.4 %, with subgroup rates of 4.0 % (GCA) and 4.2 % (TAK).

JAK inhibitors demonstrate favorable efficacy and safety in LVV.